1. Clinical & Scientific Overview
Probiotic Multi-Strain (Lactobacillus rhamnosus GG & Bifidobacterium animalis subsp. lactis BB-12 / S. boulardii) (TIP-MED-000637, Reference Code [SUP-13]) is classified under
Dietary Supplements & Nutraceuticals (FSSAI / ICMR-NIN) as a Clinical Nutrition & Nutraceutical Science • Live Non-Pathogenic Gut Microbiota Modulators.
Within the Indian regulatory and compendial framework, it is governed under FSSAI Health Supplements, Nutraceuticals, Food for Special Dietary Use, and Probiotic Food Regulations (ICMR-DBT Probiotic Guidelines)..
FSSAI Licensed Health Supplement / Nutraceutical Formulations (RDA Compliant)
FSSAI Probiotic Requirement: Viable count must be >=10^8 CFU (100 million CFU, typically 1 to 10 billion CFU) per serving at the END of shelf-life, with exact Genus, Species, and Strain alphanumeric designation declared on the label (probiotic efficacy is strictly strain-specific!).
Clinical Nutrition, ICMR-NIN RDA & FSSAI Nutraceutical Profile
Probiotic Viable Microbial Strains (LGG / BB-12 / S. boulardii)
Live Non-Pathogenic Gut Microbiota Modulators
Fermented dairy (dahi/curd, buttermilk/chaas) and lyophilized strain-specific probiotic capsules/sachets
ICMR-NIN 2024 Recommended Dietary Allowance (RDA) & Tolerable Upper Intake Limit (UL): FSSAI Probiotic Requirement: Viable count must be >=10^8 CFU (100 million CFU, typically 1 to 10 billion CFU) per serving at the END of shelf-life, with exact Genus, Species, and Strain alphanumeric designation declared on the label (probiotic efficacy is strictly strain-specific!).
Deficiency Clinical Syndromes vs Chronic Excess / Hypervitaminosis Risks: Safe in immunocompetent hosts (mild transient bloating/flatulence for 2–3 days); CONTRAINDICATED in severely immunocompromised patients, critically ill ICU patients with central venous catheters, and severe acute pancreatitis due to documented risk of Lactobacillus bacteraemia or Saccharomyces boulardii fungaemia!
Drug–Nutrient Chelation & Timing Interactions: Separate Bacterial Probiotics (Lactobacillus, Bifidobacterium) from oral Antibiotics by at least 2 hours so the antibiotic does not kill the probiotic bacteria in the gut lumen; conversely, Yeast probiotics (Saccharomyces boulardii CNCM I-745) are naturally resistant to antibacterial antibiotics, but are killed by systemic Antifungals (fluconazole, itraconazole).
FSSAI Health Supplement vs Therapeutic Drug Distinction: FSSAI Health Supplements, Nutraceuticals, Food for Special Dietary Use, and Probiotic Food Regulations (ICMR-DBT Probiotic Guidelines).
3. Mechanism of Action & Pharmacodynamics
Competitive exclusion of enteropathogens for mucin binding sites, production of L-lactic acid and short-chain fatty acids (butyrate, acetate) that lower colonic lumenal pH and nourish colonocytes, enhancement of tight-junction proteins (occludin, ZO-1), and secretory IgA stimulation.
4. Therapeutic Indications & Evidence-Supported Uses
- Physiological & Biochemical Role: Competitive exclusion of enteropathogens for mucin binding sites, production of L-lactic acid and short-chain fatty acids (butyrate, acetate) that lower colonic lumenal pH and nourish colonocytes, enhancement of tight-junction proteins (occludin, ZO-1), and secretory IgA stimulation.
- Dietary Sources: Fermented dairy (dahi/curd, buttermilk/chaas) and lyophilized strain-specific probiotic capsules/sachets
- ICMR-NIN RDA & Upper Limits: FSSAI Probiotic Requirement: Viable count must be >=10^8 CFU (100 million CFU, typically 1 to 10 billion CFU) per serving at the END of shelf-life, with exact Genus, Species, and Strain alphanumeric designation declared on the label (probiotic efficacy is strictly strain-specific!).
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: FSSAI Probiotic Requirement: Viable count must be >=10^8 CFU (100 million CFU, typically 1 to 10 billion CFU) per serving at the END of shelf-life, with exact Genus, Species, and Strain alphanumeric designation declared on the label (probiotic efficacy is strictly strain-specific!).
Administration & Meal Timing: Separate Bacterial Probiotics (Lactobacillus, Bifidobacterium) from oral Antibiotics by at least 2 hours so the antibiotic does not kill the probiotic bacteria in the gut lumen; conversely, Yeast probiotics (Saccharomyces boulardii CNCM I-745) are naturally resistant to antibacterial antibiotics, but are killed by systemic Antifungals (fluconazole, itraconazole).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Salt-form and meal-timing dependent gastrointestinal absorption; see bioavailability and drug-nutrient chelation notes (Separate Bacterial Probiotics (Lactobacillus, Bifidobacterium) from oral Antibiotics by at least 2 hours so the antibiotic does not kill the probiotic bacteria in the gut lumen; conversely, Yeast probiotics (Saccharomyces boulardii CNCM I-745) are naturally resistant to antibacterial antibiotics, but are killed by systemic Antifungals (fluconazole, itraconazole).).
Incorporated into cellular coenzyme pools, metalloproteins, or membrane phospholipids.
Caution with magnesium, potassium, calcium, vitamin D, and high-dose vitamin C/collagen (oxalate) in Chronic Kidney Disease.
Caution with fat-soluble vitamins and concentrated lipophilic extracts in hepatobiliary disease.
7. Contraindications, Precautions & High-Risk Warnings
- Supratherapeutic megadosing above the ICMR-NIN Tolerable Upper Intake Level (UL) without medical indication
- Safe in immunocompetent hosts (mild transient bloating/flatulence for 2–3 days); CONTRAINDICATED in severely immunocompromised patients, critically ill ICU patients with central venous catheters, and severe acute pancreatitis due to documented risk of Lactobacillus bacteraemia or Saccharomyces boulardii fungaemia!
Key Clinical Precautions: Safe in immunocompetent hosts (mild transient bloating/flatulence for 2–3 days); CONTRAINDICATED in severely immunocompromised patients, critically ill ICU patients with central venous catheters, and severe acute pancreatitis due to documented risk of Lactobacillus bacteraemia or Saccharomyces boulardii fungaemia!
8. Adverse Effects Profile
- Safe in immunocompetent hosts (mild transient bloating/flatulence for 2–3 days); CONTRAINDICATED in severely immunocompromised patients, critically ill ICU patients with central venous catheters, and severe acute pancreatitis due to documented risk of Lactobacillus bacteraemia or Saccharomyces boulardii fungaemia!
- Safe in immunocompetent hosts (mild transient bloating/flatulence for 2–3 days); CONTRAINDICATED in severely immunocompromised patients, critically ill ICU patients with central venous catheters, and severe acute pancreatitis due to documented risk of Lactobacillus bacteraemia or Saccharomyces boulardii fungaemia!
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Separate Bacterial Probiotics (Lactobacillus, Bifidobacterium) from oral Antibiotics by at least 2 hours so the antibiotic does not kill the probiotic bacteria in the gut lumen; conversely, Yeast probiotics (Saccharomyces boulardii CNCM I-745) are naturally resistant to antibacterial antibiotics, but are killed by systemic Antifungals (fluconazole, itraconazole).
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Verify whether the patient requires physiological nutritional maintenance (<=1 RDA under FSSAI) or high-dose therapeutic deficiency correction (Schedule H/medical supervision), and check for multi-supplement stacking.
Pharmacist Patient Counselling Points:
- Separate Bacterial Probiotics (Lactobacillus, Bifidobacterium) from oral Antibiotics by at least 2 hours so the antibiotic does not kill the probiotic bacteria in the gut lumen; conversely, Yeast probiotics (Saccharomyces boulardii CNCM I-745) are naturally resistant to antibacterial antibiotics, but are killed by systemic Antifungals (fluconazole, itraconazole).
- Check all multivitamin and wellness labels to avoid accidentally doubling up on fat-soluble vitamins (A, D, E, K), iron, or zinc.
- Health supplements support normal physiological nutrition and are NOT intended to diagnose, treat, cure, or prevent disease under Section 22 of the FSS Act, 2006.
Storage, Stability & Dispensing Safeguards: Store in a cool, dry place below 25°C away from moisture and direct sunlight; verify FSSAI License Number and Veg/Non-Veg symbol on packaging.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: ICMR-NIN (National Institute of Nutrition) Nutrient Requirements and Recommended Dietary Allowances (RDA) for Indians (2020/2024); FSSAI (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food and Novel Food) Regulations, 2022.
Official Verification Portals: ICMR-National Institute of Nutrition (NIN) — Dietary Guidelines & Nutrient Requirements for Indians • FSSAI — Food Safety and Standards (Health Supplements and Nutraceuticals) Regulations
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.